Chinese version of press release, click here: https://www.terumobct.com/Pages/News/Press%20Releases/CN-Terumo-Blood-and-Cell-Technologies-Reaches-Strategic-Partnership-With-Shandong-Institute-of-Medical-Devices-and-Pharmace.aspx
Hangzhou, China – Terumo Blood and Cell Technologies (Terumo BCT), a global medical technology company specializing in blood and cell processing, has signed a Memorandum of Understanding (MoU) on a strategic partnership with the Shandong Institute of Medical Devices and Pharmaceutical Packaging Inspection. The partnership aims to build a comprehensive platform integrating production, academia, research and application, through which both parties will strengthen exchanges and collaboration in the medical device field. Additionally, the partnership will deepen academic research, promote cutting-edge technologies and improve the skills and capacities of industry professionals, thereby injecting fresh dynamics into the innovative development of China’s medical and health industry.
Founded in 1987, the Shandong Institute of Medical Devices and Pharmaceutical Packaging Inspection is among China's top 10 state-level medical device inspection centers. The institute now has 270 employees, with 92% of them being technical specialists and 62% holding master's and doctoral degrees, showcasing the organization's strong technical strength and profound professional capacity. Building on its senior team of experts, the institute actively participates in the revision of international ISO standards and the formulation of domestic standards and guidelines for medical devices and pharmaceutical packaging materials. With such efforts, it has made outstanding contributions to the improvement and development of medical device industry standards in China.
Picture: Wan Min, Dean of the Shandong Institute of Medical Devices and Pharmaceutical Packaging Inspection, delivered a speech at the signing ceremony
Wan Min, Dean of the Shandong Institute of Medical Devices and Pharmaceutical Packaging Inspection noted, "After years of close cooperation, we have built a solid foundation for collaborative partnership with Terumo BCT. The signing of the MoU also marks the first time that we've reached such a partnership at the corporate level, which is of great strategic significance. Through the move, we hope to accelerate the deep-level integration of production, academia, research and application, promote the efficient conversion of research fruits, facilitate the innovation-driven transformation of China's medical and health industry, enhance the industry's resilience and modernization, further boost its competitiveness on the international stage and provide strong support for cultivating new quality productive forces and serving the Healthy China initiative."
According to the MoU, Terumo BCT and the institute have agreed to further deepen collaborative partnership in the medical device field. The two parties will work together to strengthen technical research and innovation, with a focus on Terumo BCT's strategic product areas, including comprehensive solutions in the fields of blood component collection and processing, as well as therapeutic apheresis and cell therapy technology, to help treat serious diseases and address unmet medical needs. Both parties promise to actively collaborate on the development, promotion and training of international, national and industry standards related to medical devices and to jointly improve industry norms and technical capacities. In addition, together they will co-conduct research on the entire life cycle of medical devices, covering all stages from product development to post-market evaluation, so as to enhance the effective supply of medical devices and jointly promote the high-quality development of the medical and health industry.
Antoinette Gawin, President and CEO of Terumo BCT, delivered a speech at the signing ceremony
Antoinette Gawin, President and CEO of Terumo BCT, stated: "We are honored to have reached the MoU with the Shandong Institute of Medical Devices and Pharmaceutical Packaging Inspection, marking an important milestone for Terumo BCT on its localization journey. From lifesaving transfusions to next-generation therapies that treat cancer and other diseases, blood and cells are essential medicine to meet the needs of patients. We look forward to strengthening resource sharing and technical exchanges with the institute, creating more possibilities through shared efforts, and contributing our strength to promoting industry progress and improving people's health."
About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today.
Terumo Blood and Cell Technologies customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 150 countries. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology. For more information, visit TERUMOBCT.COM.